Aspirin Reduces Risks of Antiphospholipid Syndrome
Aspirin reduces risks in pregnant women with antiphospholipid syndrome. Antiphospholipid syndrome birth rate was uneventful in women who took Aspirin ® as a preventive measure increased from 38% to 72%.
The administration of Aspirin ® significantly reduces the risk of complications in patients with antiphospholipid syndrome, according to research conducted by Dr. Munoz Rodriguez, who has been promoted by the Hospital Clinic of Barcelona and the Institute of Biomedical Research August i Sunyer The study, whose findings are published in the journal Seminars in Arthritis and Rheumatism, shows that Aspirin consumption lowers the chances of occurrence of venous or arterial thrombosis and abortions, usually related complications with this autoimmune condition.
Specifically, the uneventful birth rate rises from 38% to 72% in pregnant women taking Aspirin ® as a preventive measure.
Research conducted by Dr. Munoz Rodriguez team focused on one hundred patients with antiphospholipid syndrome who underwent a follow-up period of over four years. The specialists found that 91% of patients not treated with aspirin developed new thrombosis, while those who were given Aspirin ® that risk was reduced to 42%.
The long term treatment with anticoagulants was found to be even more effective: only 19% of subjects who received him were affected by new episodes of thrombosis. Aspirin was especially good effect in pregnant women undergoing prophylactic treatment with Aspirin ®.
Antiphospholipid syndrome is an autoimmune disorder characterized by paintings of arterial and venous thrombosis, abortions, or thrombocytopenia in association with the presence of antiphospholipid antibodies. The syndrome is considered primary if not associated with other underlying disease and secondary if it is linked to other autoimmune diseases such as systemic lupus erythematosus.